Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

Table 3

Distribution of major anticholinergic adverse events in each group over 52 weeks.

Variable, n (%)	Imidafenacin	Solifenacin	P-value
N (safety population)	21	20
Dry mouth	15 (71.4%)	18 (90.0%)	0.2379^b
Mild	8 (38.1%)	4 (20.0%)
Moderate	7 (33.3%)	10 (50.0%)	0.0092^a
Severe	0 (0%)	4 (20.0%)
Constipation	3 (14.3%)	13 (65.0%)	0.0013^b
Blurred vision	2 (9.5 %)	7 (35.0%)	0.0670^b

The severity of dry mouth was evaluated on a 3-point scale: mild, barely noticeable; moderate, tolerable after drinking water; severe, intolerable after drinking water, leading to discontinuation of the investigational drug;
a: Mann-Whitney U test, b: Fisher exact test, two-sided.